AllianceBernstein
PTGX icon

AllianceBernstein’s Protagonist Therapeutics PTGX Stock Holding History

AllianceBernstein’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.39M Buy
79,563
+5,773
+8% +$603K ﹤0.01% 1272
2026
Q1 		$6.44M Buy
73,790
+568
+0.8% +$50.3K ﹤0.01% 1419
2025
Q4 		$6.4M Sell
73,222
-187,632
-72% -$15.4M ﹤0.01% 1423
2025
Q3 		$17.3M Buy
260,854
+192,954
+284% +$11M 0.01% 978
2025
Q2 		$3.75M Hold
67,900
– – ﹤0.01% 1610
2025
Q1 		$3.28M Sell
67,900
-325
-0.5% -$13.6K ﹤0.01% 1639
2024
Q4 		$2.63M Sell
68,225
-13,694
-17% -$597K ﹤0.01% 1821
2024
Q3 		$3.69M Sell
81,919
-13,250
-14% -$535K ﹤0.01% 1661
2024
Q2 		$3.3M Buy
95,169
+9,769
+11% +$286K ﹤0.01% 1681
2024
Q1 		$2.47M Hold
85,400
– – ﹤0.01% 1806
2023
Q4 		$1.96M Sell
85,400
-1,872
-2% -$32.8K ﹤0.01% 1950
2023
Q3 		$1.46M Buy
87,272
+7,072
+9% +$137K ﹤0.01% 2050
2023
Q2 		$2.22M Buy
80,200
+26,000
+48% +$651K ﹤0.01% 1842
2023
Q1 		$1.25M Hold
54,200
– – ﹤0.01% 2118
2022
Q4 		$591K Buy
54,200
+14,200
+36% +$120K ﹤0.01% 2538
2022
Q3 		$337K Sell
40,000
-6,000
-13% -$56.8K ﹤0.01% 2817
2022
Q2 		$364K Sell
46,000
-80,463
-64% -$973K ﹤0.01% 2819
2022
Q1 		$3M Buy
126,463
+80,563
+176% +$2.27M ﹤0.01% 1850
2021
Q4 		$1.57M Hold
45,900
– – ﹤0.01% 2270
2021
Q3 		$813K Hold
45,900
– – ﹤0.01% 2577
2021
Q2 		$2.06M Buy
45,900
+15,300
+50% +$505K ﹤0.01% 2172
2021
Q1 		$793K Buy
30,600
+2,600
+9% +$65.8K ﹤0.01% 2494
2020
Q4 		$564K Hold
28,000
– – ﹤0.01% 2542
2020
Q3 		$547K Hold
28,000
– – ﹤0.01% 2482
2020
Q2 		$494K Buy
28,000
+11,900
+74% +$149K ﹤0.01% 2623
2020
Q1 		$114K Buy
16,100
+3,500
+28% +$26.2K ﹤0.01% 2928
2019
Q4 		$89K Hold
12,600
– – ﹤0.01% 3052
2019
Q3 		$151K Buy
+12,600
New +$159K ﹤0.01% 3008

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein's PTGX Position: Q2 2026 in Review

AllianceBernstein increased its Protagonist Therapeutics (PTGX) stake by 7.8% in Q2 2026, buying an estimated $603K and bringing the position to 79,563 shares worth $8.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1272.

AllianceBernstein first reported a position in PTGX in Q3 2019 and has held it in 28 quarters since. The position peaked at $17.3M in Q3 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • AllianceBernstein held 79,563 shares of Protagonist Therapeutics worth $8.39M as of Q2 2026.
  • AllianceBernstein bought 5,773 Protagonist Therapeutics shares in Q2 2026, an estimated $603K.
  • Protagonist Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1272 holding.
  • AllianceBernstein first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • AllianceBernstein's Protagonist Therapeutics position peaked at $17.3M in Q3 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.